🔴 Iovance Biotherapeutics is trading 4.6% down in pre-market amid unexplained trading pressure

Iovance Biotherapeutics is trading 4.6% down at $6.71 in pre-market amid unexplained trading pressure, with no clear company-specific catalyst identified.

• It closed at $7.03 on August 18, 2026.
• The latest identified material catalyst was the August 6 earnings report, which showed record second-quarter revenue of approximately $99.3 million and strong Amtagvi demand.
• No new company-specific announcement, earnings release, FDA action, or analyst change clearly explains the decline; broader biotech is higher pre-market.